title: [Study of developing clinical outbreak and serological rebounds in children with congenital toxoplasmosis and follow-up during the first 2 years of life].
abstract: BACKGROUND
  The survival of T gondii bradyzoites in cysts explains clinical recurrences and serological rebounds after birth in children with congenital toxoplasmosis. At the present time, management of such manifestations is not well defined.
  
  
  METHODS
  Sixty-three infants with congenital toxoplasmosis were followed-up at the University Hospital of Lille (France) during the first two years of life. For each child, the treatment before and after birth was well defined. Clinical, ophthalmological, radiological and serological data were collected every third month. Serological assays specially adapted to this age bracket were used for the quantification of specific IgG, or for the detection of T gondii specific IgM and IgA.
  
  
  RESULTS
  Seventy-six serological rebounds were reported in 55 of the 63 children (87%). They concerned essentially IgG (96%) and less frequently IgM (47%) or IgA (60%). At the same time, only five clinical recurrences were observed, four of them being preceded by a serological rebound.
  
  
  CONCLUSIONS
  Treatment of fetuses or children with pyrimethamine and sulfonamides versus spiramycin alone was associated with a decrease in the frequency of serological rebounds during the first year of life (P < 0.001). Such a therapeutic regimen during the second year of life decreases the appearance of serological rebounds in children without rebound antecedent (P < 0.001).
  
  
  CONCLUSIONS
  The increase in number of rebounds after the end of a course of pyrimethamine and sulfonamides necessitates the evaluation of such a long term treatment without interruption.
authors.affiliation: Laboratoire de parasitologie-mycologie, CHRU, Lille, France.
authors.forename: B
authors.initials: B
authors.lastname: Fortier
authors.forename: C
authors.initials: C
authors.lastname: Coignard-Chatain
authors.forename: A
authors.initials: A
authors.lastname: Dao
authors.forename: V
authors.initials: V
authors.lastname: Rouland
authors.forename: A S
authors.initials: AS
authors.lastname: Valat
authors.forename: D
authors.initials: D
authors.lastname: Vinatier
authors.forename: T
authors.initials: T
authors.lastname: Lebrun
mesh_terms: D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007157:Immunologic Surveillance; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy; D014123:Toxoplasmosis / Q000188:drug therapy; D014125:Toxoplasmosis, Congenital / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M